YNIOS PHARMA set out to build a platform for oral or parenteral administration of inflammation treatment found in acute situations and chronic inflammatory diseases.

YNIOS PHARMA is developing a preclinical program to demonstrate its effectiveness in modulating acute systemic inflammatory responses, protecting vital organs and promoting faster patient recovery.

These acute systemic inflammatory responses can also develop into different situations such as acute ischemic stroke, acute myocardial infarction, severe acute respiratory syndrome (SARS), pancreatitis, major surgery, trauma and burns.

YNIOS PHARMA is a biotech founded in March 2022 by Philippe Van Wesepoel and Jean François Plucker, the same founders of biotech OLYS Pharma which focusses on topical neuro-cutaneous treatments. *

* Diabetic Peripheral Neuropathic Pain – Neuralgia of the trigeminocervical complex (Migraine) – Low back pain – Sciatica pain – Rheumatoid arthritis pain.


JF. Plucker
JF. PluckerCo-founder & COO
Partner of an intellectual property firm in Brussels, Jean François worked for clients in many countries, before moving to the United States where he specialized in technology transfers between university or federal laboratories and private industrial companies. Combining scientific and economic logics became its strength, where the two logics usually clash. He puts his international experience at the service of humanly useful and economically promising projects. Co-founder of YNIOS PHARMA, he brings a seasoned experience in management, international trade and intellectual property in the development of the Start-Up.
Ph. Van Wesepoel
Ph. Van WesepoelCo-founder & CSO
With a scientific background and an MBA, Philippe has experience in different therapeutic areas of the pharmaceutical industry demonstrating both his practicality and his scientific rigor. His curiosity and determination allow him to get to the bottom of things with a focus on improving quality of life. YNIOS PHARMA’s values and mission suit him well: develop more effective and well-tolerated therapeutic solutions thanks to a new concept that makes it a breakthrough innovation.


The founders are the Associate Directors of the company. They combine extensive experience in management, international business development, intellectual property, research and innovation, and partnership strategies.